Connor, Clark & Lunn Investment Management (CC&L)’s Enanta Pharmaceuticals ENTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.59M Buy
125,759
+21,856
+21% +$293K ﹤0.01% 1022
2025
Q4
$1.64M Buy
103,903
+26,397
+34% +$335K ﹤0.01% 984
2025
Q3
$928K Buy
77,506
+62,710
+424% +$501K ﹤0.01% 1087
2025
Q2
$112K Sell
14,796
-15,669
-51% -$94.3K ﹤0.01% 1455
2025
Q1
$168K Buy
30,465
+5,829
+24% +$36K ﹤0.01% 1337
2024
Q4
$142K Buy
24,636
+12,868
+109% +$123K ﹤0.01% 1351
2024
Q3
$122K Buy
+11,768
New +$154K ﹤0.01% 1362
2024
Q2
Sell
-44,629
Closed -$779K 1471
2024
Q1
$779K Buy
44,629
+3,264
+8% +$43.2K ﹤0.01% 960
2023
Q4
$389K Buy
+41,365
New +$385K ﹤0.01% 1114
2022
Q4
Sell
-5,110
Closed -$265K 1278
2022
Q3
$265K Buy
+5,110
New +$299K ﹤0.01% 940
2020
Q3
Sell
-9,911
Closed -$498K 980
2020
Q2
$498K Buy
+9,911
New +$513K ﹤0.01% 756
2019
Q4
Sell
-7,950
Closed -$478K 968
2019
Q3
$478K Buy
7,950
+5,300
+200% +$394K ﹤0.01% 693
2019
Q2
$224K Buy
+2,650
New +$238K ﹤0.01% 883
2019
Q1
Sell
-3,100
Closed -$220K 945
2018
Q4
$220K Sell
3,100
-1,200
-28% -$92K ﹤0.01% 831
2018
Q3
$367K Buy
+4,300
New +$431K ﹤0.01% 752
2015
Q1
Sell
-5,300
Closed -$270K 585
2014
Q4
$270K Sell
5,300
-4,200
-44% -$188K ﹤0.01% 477
2014
Q3
$376K Buy
+9,500
New +$379K ﹤0.01% 424
2014
Q2
Sell
-10,000
Closed -$441K 559
2014
Q1
$441K Buy
+10,000
New +$363K ﹤0.01% 504

Other funds holding ENTA